Abstract
You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy I1 Apr 2017MP70-13 CRYOSURGICAL ABLATION OF THE PROSTATE: LOCAL DISEASE CONTROL FOR INTERMEDIATE /HIGH-GRADE GLEASON PROSTATE CANCER Ahmed El Shafei, Mohamed Eltemamy, Yaw Nyame, Hans Arora, and J Stephen Jones Ahmed El ShafeiAhmed El Shafei More articles by this author , Mohamed EltemamyMohamed Eltemamy More articles by this author , Yaw NyameYaw Nyame More articles by this author , Hans AroraHans Arora More articles by this author , and J Stephen JonesJ Stephen Jones More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2289AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Our objective is to report local disease control after primary whole gland cryoablation when used to treat Gleason ≥ 7 localized prostate cancers at our institution. METHODS We analyzed 134 prostate cryoablation patients who had a Gleason score of ≥ 7 who underwent primary whole gland cryoablation. Progression free survival (PFS) was defined according to Phoenix definition of PSA nadir +2 ng/ml. Among the biochemical failure (BF) patients, we assessed local disease control by postoperative prostate biopsy, pelvic MRI or CT. BS was used to assess metastatic disease. We defined local treatment failure by a positive post cryoablation prostate biopsy and/or MRI/CT scan findings suggesting local recurrence within the prostate. RESULTS PFS was noted in 101 patients (75%) with median follow up time of 31.5 months. Among the 33 patients who showed BF, 3 patients did not have a metastatic workup. Of the remaining 30 patients, 15 (11.2% of treated patients) showed only local treatment failure as indicated by positive post cryoablation prostate biopsy and/or MRI/CT scan findings suggesting local recurrence within the prostatic gland. The other 15 patients (11.2%) showed metastatic disease with no evidence of local treatment failure. (Table 1) CONCLUSIONS Cryoablation is a successful primary treatment option for patients with intermediate/high grade prostate cancer. Up to half of patients who showed biochemical failure had good local disease control but had distant failure as evident by post cryoablation prostate biopsy and/or MRI/CT scans; this suggests patient selection failing to identify micro metastasis present at the time of treatment rather than local treatment failure. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e940 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Ahmed El Shafei More articles by this author Mohamed Eltemamy More articles by this author Yaw Nyame More articles by this author Hans Arora More articles by this author J Stephen Jones More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have